echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Assessment of coronary heart disease and ischemic stroke, the latest guidelines are coming!

    Assessment of coronary heart disease and ischemic stroke, the latest guidelines are coming!

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cardiovascular and cerebrovascular diseases have become the most important diseases that endanger the health and life of Chinese residents, and are also the main diseases
    that cause the loss of life expectancy, poverty due to illness, and return to poverty due to illness.


    Assessment of coronary heart disease



    (1) Stable angina chest pain symptom assessment


    The severity of angina is divided into 4 levels
    .



    • Level 1: general physical activity (walking and ascent) is not restricted, but angina occurs when strong, fast, or sustained exertion;

    • Level 2: Mild restriction of physical activity in general, angina pectoris in rapid walking, after meals, cold, mental stress, and several hours after waking up, and angina pectoris occur when walking more than 200 meters on the ground or climbing the first floor of the building under normal circumstances;

    • Level 3: General physical activity is obviously limited, generally walking within 200 meters of flat ground or climbing the 1st floor of the building to develop angina;

    • Level 4: Angina can occur with light activity or rest
      .


    (2) Recurrence of unstable angina / myocardial infarction

    Recurrent unstable angina or myocardial infarction may be considered in patients in the stable phase after medication, PCI, and coronary artery bypass grafting:

    (1) Frequent angina in the past 1 month;

    (2) (spontaneous) angina at rest;

    (3) Chest pain lasts longer, the degree is severe, and it is not easy to be relieved
    by nitroglycerin.


    Assessment of ischemic stroke



    (1) The stage of ischemic stroke is divided into acute stages
    according to the course of the disease: within 1 month after the onset of the disease, the condition is the most serious and requires timely and correct treatment; Recovery period: 2 to 6 months after the onset of the disease, through treatment, secondary prevention and TCM physiotherapy, TCM rehabilitation and other measures, the symptoms of acute neurological dysfunction are improved; Sequelae phase: more than 6 months after the onset of the disease, vital signs are stable, signs and symptoms are no longer progressing, and there may be a certain degree of sequelae
    .


    (1) Weakness or numbness of the newly emerging limb (with or without face);

    (2) Numbness or crooked corners of the mouth in the newly emerging side;

    (3) Unable to speak clearly or have difficulty understanding language;

    (4) Gaze to one side with both eyes;

    (5) Loss or blurring of vision in one or both eyes;

    (6) Vertigo with vomiting;

    (7) Rare severe headache and vomiting;

    (8) The above symptoms are accompanied by impaired consciousness or convulsions
    .


    Risk assessment for cardiovascular events with cardio-cerebral comorbidities



    Patients with cardiocerebral comorbidities were identified as ultra-high-risk patients with atherosclerotic cardiovascular disease, and treatment decisions and risk factor control goals
    were determined on this basis.



    Diagnosis and evaluation process of coronary heart disease and ischemic stroke are co-existent



    The above content is excerpted from: Beijing Hypertension Prevention and Control Association, Chinese Stroke Society Hypertension Prevention and Management Branch, China Geriatric Health Care Association Pension and Health Professional Committee.
    Wait.
    Expert consensus on the management of primary coronary heart disease and ischemic stroke[J].
    Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, 2022, 22(04): 1-19.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.